肼羧酸,1-环戊基-,1,1-二甲基乙基酯 | 259870-74-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 肼羧酸,1-环戊基-,1,1-二甲基乙基酯
• 中文别名: 2-甲基-2-丙基1-环戊基肼羧酸酯
• 英文名称: 1-cyclopentyl-1-tert-butoxycarbonylhydrazine
• 英文别名: tert-butyl 1-cyclopentylhydrazinecarboxylate；tert-butyl N-amino-N-cyclopentylcarbamate
• CAS: 259870-74-1
• 化学式: C₁₀H₂₀N₂O₂
• 分子量: 200.281
• InChiKey: IUXCTZBYXZBUNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  肼羧酸,1-环戊基-,1,1-二甲基乙基酯 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 环戊肼盐酸盐
  参考文献：
  名称：

  N-tert-Butoxycarbonylaminophthalimide, a versatile reagent for the conversion of alcohols into alkylated tert-butylcarbazates or hydrazines via the Mitsunobu protocol

  摘要：

  An efficient two-step method has been developed for the conversion of alcohols to substituted hydrazines. The use of N-tert-butoxycarbonylaminophthalimide as an acid partner in Mitsunobu reactions with a variety of alcohols permits the synthesis of the corresponding monoalkylated tert-butylcarbazates and hydrazines. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)02038-9
• 作为产物：
  描述：

  1,3-二氧代异吲哚啉-2-氨基甲酸叔丁酯 在 三苯基膦 、 甲基肼 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 肼羧酸,1-环戊基-,1,1-二甲基乙基酯
  参考文献：
  名称：

  使用Mitsunobu协议通过N-酰基或N-烷氧基羰基氨基邻苯二甲酰亚胺的烷基化反应合成1,1取代的肼。

  摘要：

  N-酰基和N-烷氧基羰基氨基邻苯二甲酰亚胺使用方便的反应制备，并有效地用作Mitsunobu反应中的酸伙伴。该反应使它们被伯，仲或苄基烷基化。这些N-取代的氨基邻苯二甲酰亚胺的反应性和pK（a）值的比较表明，在这种情况下，Mitsunobu反应的成功似乎更多地取决于空间而不是电子效应。最终的脱邻苯二甲酰化步骤导致制备1，1-取代肼的有效方法。

  DOI：

  10.1021/jo000225s

文献信息

• [EN] 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS<br/>[FR] ANALOGUES DE 3-FURANYLE DE TOXOFLAVINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004007499A1

  公开（公告）日：2004-01-22

  The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer being 0 or 1; n represents an integer being 0, 1 or 2; R1 represents C1-4alkyl, C1-4alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C1-4-alkyloxycarbonyl; R2 represents hydrogen or C1-4 alkyl; R3 represents hydrogen or C1-4alkyl; or R2 and R3 taken together with the carbon atom to which they are attached form cyclopentyl or piperidinyl wherein said cyclopentyl or piperidinyl each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C1-4alkyloxycarbonyl, phenylcarbonyl or -C(=NH)-NH2; R4 represents halo or C1-4alkyloxy; R5 represents Het2, C1-4alkyl substituted with one or where possible more substituents being selected from hydroxy, halo, Het3 or NR6R7, or C1-4alkyloxy substituted with one or where possible more substituents being selected from Het4 or -C(=O)-Het4; R6 and R7 are each independently selected from hydrogen, C1-4alkyl, Het5 or C1-4alkyl substituted with one or where possible more substituents being selected from hydroxy or Het5; Het2 represents piperazinyl; Het3 represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C1-4alkyl preferably methyl, aminosulfonyl, mono- or di(C1-4alkyl)aminosulfonyl, hydroxyC1 -4alkyloxyC1-4alkyl, C1-4alkyloxyC1-4alkyl or C1-4alkyloxy; Het4 represents a heterocycle selected from morpholinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three C1-4alkyl substituents, preferably methyl; Het5 represents a heterocycle selected from pyridinyl, pyrrolidinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, C1-4alkyloxycarbonyl or mono- or di(C1-4alkyl)aminosulfonyl.

  本发明涉及具有式（I）的化合物，其N-氧化物形式，药用可接受的加合物盐及其立体化异构体形式，其中m代表为0或1的整数；n代表为0，1或2的整数；R1代表C1-4烷基，带有吡啶基，苯基，哌啶基或带有C1-4-烷氧羰基的C1-4烷基；R2代表氢或C1-4烷基；R3代表氢或C1-4烷基；或R2和R3与它们连接的碳原子一起形成环戊烷基或哌啶基，其中所述的环戊烷基或哌啶基各自可以选择性地被一个，或在可能的情况下，两个或三个取代基取代，每个取代基独立地选择自C1-4烷氧羰基，苯甲酰基或-C（=NH）-NH2；R4代表卤素或C1-4烷氧基；R5代表Het2，带有一个或在可能的情况下更多取代基的C1-4烷基，所选取的取代基包括羟基，卤素，Het3或NR6R7，或带有一个或在可能的情况下更多取代基的C1-4烷氧基，所选取的取代基包括Het4或-C（=O）-Het4；R6和R7各自独立选择自氢，C1-4烷基，Het5或带有羟基或Het5的C1-4烷基取代基；Het2代表哌嗪基；Het3代表从吗啉基，吡咯啉基，哌啶基或哌嗪基中选择的杂环，其中所述的单环杂环可以选择性地被一个，或在可能的情况下，两个或三个取代基取代，每个取代基独立地选择自C1-4烷基（最好是甲基），氨基磺酰基，单烷基或双烷基氨基磺酰基，羟基C1-4烷氧基C1-4烷基，C1-4烷氧基C1-4烷基或C1-4烷氧基；Het4代表从吗啉基或哌嗪基中选择的杂环，其中所述的单环杂环可以选择性地被一个，或在可能的情况下，两个或三个C1-4烷基取代基取代，最好是甲基；Het5代表从吡啶基，吡咯啉基或哌啶基中选择的杂环，其中所述的单环杂环可以选择性地被一个，或在可能的情况下，两个或三个取代基取代，每个取代基独立地选择自氨基磺酰基，C1-4烷氧羰基或单烷基或双烷基氨基磺酰基。
• Orthogonal Regioselective Synthesis of N-Alkyl-3-substituted Tetrahydroindazolones
  作者：Jonghoon Kim、Heebum Song、Seung Bum Park

  DOI：10.1002/ejoc.201000516

  日期：——

  A divergent strategy for the regioselective and orthogonal synthesis of complementary regioisomers of N-alkyl-3-substituted-tetrahydroindazolones 3 and 4 was achieved from Boc-protected alkylhydrazines 1. The robustness and substrate generality of this method were validated by synthesizing 3 and 4 through the intra- and intermolecular condensation of 1 with various 2-acylcyclohexane-1,3-diones 2 and

  从 Boc 保护的烷基肼 1 中实现了区域选择性和正交合成 N-烷基-3-取代四氢吲唑酮 3 和 4 的互补区域异构体的不同策略。通过合成 3 和 4 验证了该方法的稳健性和底物通用性1 分别与各种 2-酰基环己烷-1,3-二酮 2 和醛的分子内和分子间缩合。
• Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20040204454A1

  公开（公告）日：2004-10-14

  The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: P 4 -M-M 4 I or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了公式I：P4-M-M4I或其药学上可接受的盐形式的含有内酰胺的环状二胺及其衍生物，其中M是非芳香性碳环或杂环。本发明化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是因子Xa的抑制剂。
• LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：Qiao X Jennifer

  公开号：US20070135428A1

  公开（公告）日：2007-06-14

  The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: P 4 -M-M 4 I or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了公式I：P4-M-M4I或其药学上可接受的盐形式的含有内酰胺的环状二胺及其衍生物，其中M为非芳香族碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是Xa因子的抑制剂。
• KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Flynn Daniel L.

  公开号：US20120289540A1

  公开（公告）日：2012-11-15

  The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及新型激酶抑制剂和调节剂化合物，可用于治疗各种疾病。更具体地说，本发明涉及这种化合物、激酶/化合物加合物、治疗疾病的方法以及化合物的合成方法。优选地，这些化合物可用于调节Raf激酶及其疾病多态性的激酶活性。本发明的化合物在哺乳动物癌症治疗中特别是人类癌症治疗中，包括但不限于恶性黑色素瘤、结直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤等方面有用。本发明的化合物还在类风湿性关节炎和视网膜病变，包括糖尿病视网膜神经病变和黄斑变性的治疗中有用。